--- title: "Weekly Recap | Roivant Sciences +0.28%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/296670492.md" description: "Roivant Sciences (ROIV) edged up 0.28% this week to close at $36.30, outpacing the S&P 500, which fell 1.43%, by roughly 1.71 percentage points. The stock saw a volatile, roller-coaster week: it dipped to an intraweek low of $35.65 on Monday (Aug 17) before rebounding sharply. The rally continued through Tuesday and Wednesday, with the stock hitting a weekly high of $37.97 on Wednesday, only to give back those gains in the final two sessions and settle back at $36.30." datetime: "2026-08-22T05:38:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296670492.md) - [en](https://longbridge.com/en/news/296670492.md) - [zh-HK](https://longbridge.com/zh-HK/news/296670492.md) generator: "portal-rs" --- # Weekly Recap | Roivant Sciences +0.28%, most brokers rate it buy ## The Week Roivant Sciences (ROIV) edged up 0.28% this week to close at $36.30, outpacing the S&P 500, which fell 1.43%, by roughly 1.71 percentage points. The stock saw a volatile, roller-coaster week: it dipped to an intraweek low of $35.65 on Monday (Aug 17) before rebounding sharply. The rally continued through Tuesday and Wednesday, with the stock hitting a weekly high of $37.97 on Wednesday, only to give back those gains in the final two sessions and settle back at $36.30. The weekly amplitude of 6.41% was higher than recent averages, signalling a widening divergence between buyers and sellers. ## Key Events This week’s narrative was dominated by insider selling. Among the six news items released during the period, four centred on the same story: a series of share disposals by President and CIO Mayukh Sukhatme. The week opened on a positive note, with Jefferies reiterating a ‘buy’ rating on Tuesday evening. However, attention quickly pivoted to Sukhatme’s transactions. A Wednesday filing showed he had offloaded roughly $24.12 million in common shares, and a subsequent disclosure on Saturday revealed a further sale worth about $12.47 million. While these moves are likely part of a pre-arranged trading plan, the concentrated selling by a top executive presented a notable counterpoint to the constructive analyst call earlier in the week. ## Analyst Ratings The sell-side consensus on Roivant Sciences remains firmly positive. A total of 12 analysts cover the stock: 9 rate it ‘buy’, 2 rate it ‘overweight’, and 1 rates it ‘hold’. No analyst has a ‘sell’ or ‘underweight’ rating on the stock. The consensus rating is a ‘strong buy’, with a consensus target price of $41.82, suggesting a 15.2% upside from the week’s close of $36.30. The price targets range from a low of $37.00 to a high of $50.00, highlighting a wide gap in views on the company’s long-term pipeline value. Within the biotech sector, ROIV ranks 94th out of 505 stocks, placing it in the upper-middle tier. ## The Week Ahead With no company-specific catalysts on the immediate horizon, the focus shifts to the macroeconomic calendar. On Tuesday (Aug 25), the US is set to release a raft of data, including the FHFA House Price Index, the Case-Shiller 20-City Index, the Consumer Confidence Index, and new home sales figures. The Consumer Confidence Index, with a prior reading of 90.8 and a forecast of 90.1, will be a key gauge of economic sentiment. For a high-beta biotech name like ROIV, broader market mood can be a more immediate price driver than internal developments, making these data points a critical watch in the coming days. ## In Short ROIV outperformed a declining market this week, but the signals beneath the surface were mixed. The analyst community remains supportive, with a consensus target implying a double-digit upside, yet the concentrated selling by a top insider introduced a layer of caution. The latest daily flow data shows large-lot money acting as a net seller, while small and medium trades were more active. This snapshot, when set against the stock’s intraweek reversal, hints at short-term profit-taking tendencies. Going forward, the market will be looking for concrete pipeline or commercial progress to counterbalance the insider activity, with macro data serving as the next potential catalyst in the near term. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md) ## Related News & Research - [Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock](https://longbridge.com/en/news/296663712.md) - [Roivant Sciences (NASDAQ:ROIV) Insider Sells 284,707 Shares](https://longbridge.com/en/news/296330990.md) - [Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 million](https://longbridge.com/en/news/296660931.md) - [Roivant Sciences President & CIO Sold Shares Worth Over $24M](https://longbridge.com/en/news/296285296.md) - [Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares](https://longbridge.com/en/news/296284164.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**